Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade C 99.56 1.44% 1.41
BMRN closed up 1.44 percent on Tuesday, September 18, 2018, on 1.16 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical BMRN trend table...

Date Alert Name Type % Chg
Sep 18 Crossed Above 20 DMA Bullish 0.00%
Sep 18 Bollinger Band Squeeze Range Contraction 0.00%
Sep 18 Outside Day Range Expansion 0.00%
Sep 17 Fell Below 20 DMA Bearish 1.44%
Sep 17 Bollinger Band Squeeze Range Contraction 1.44%
Sep 14 20 DMA Support Bullish 0.15%
Sep 14 Bollinger Band Squeeze Range Contraction 0.15%
Sep 13 MACD Bullish Signal Line Cross Bullish -0.01%
Sep 13 Bollinger Band Squeeze Range Contraction -0.01%
Sep 13 Multiple of Ten Bearish Other -0.01%

Older signals for BMRN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Is BMRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 106.2
52 Week Low 75.81
Average Volume 1,102,271
200-Day Moving Average 90.4991
50-Day Moving Average 100.4388
20-Day Moving Average 98.667
10-Day Moving Average 98.029
Average True Range 2.2328
ADX 10.36
+DI 16.6808
-DI 17.303
Chandelier Exit (Long, 3 ATRs ) 95.2416
Chandelier Exit (Short, 3 ATRs ) 101.8584
Upper Bollinger Band 101.5687
Lower Bollinger Band 95.7653
Percent B (%b) 0.65
BandWidth 5.881804
MACD Line -0.3606
MACD Signal Line -0.5332
MACD Histogram 0.1726
Fundamentals Value
Market Cap 17.45 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -93.05
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 102.83
Resistance 3 (R3) 102.58 101.25 102.29
Resistance 2 (R2) 101.25 100.41 101.37 102.10
Resistance 1 (R1) 100.40 99.90 100.83 100.65 101.92
Pivot Point 99.07 99.07 99.28 99.19 99.07
Support 1 (S1) 98.22 98.23 98.65 98.47 97.20
Support 2 (S2) 96.89 97.72 97.01 97.02
Support 3 (S3) 96.04 96.89 96.84
Support 4 (S4) 96.29